Characterization of Cerebral Amyloid Deposition With 18F‐Flutemetamol PET and of Glucose Metabolism With 18F‐FDG PET in Individuals Enrolled in the ALFA Project.
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Fludeoxyglucose F-18 (Primary) ; Flutemetamol-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- 01 Mar 2017 Planned End Date changed from 1 Jun 2019 to 1 Mar 2020.
- 01 Mar 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Mar 2019.
- 01 Mar 2017 Status changed from not yet recruiting to recruiting.